Cite
HARVARD Citation
Kaufman, H. et al. (2017). Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. Journal for immunotherapy of cancer. 5 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kaufman, H. et al. (2017). Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. Journal for immunotherapy of cancer. 5 (1), p. . [Online].